GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5%
Tue, 1 Sep

GLENMARK PHARMA has announced its results for the quarter ended June 2020. Here is a detailed performance review of the same:

GLENMARK PHARMA Quarterly Financials

No. of Mths
Qtr. Ending
3
Jun-19*
3
Mar-20*
3
Jun-20*
QoQ ChangeYoY Change
Net SalesRs m23,22927,67523,448-15.3%0.9%
Other incomeRs m1744158532.6%3406.0%
TurnoverRs m23,24528,11624,033-14.5%3.4%
ExpensesRs m19,81023,01818,667-18.9%-5.8%
Gross profitRs m3,4194,9865,0611.5%48.0%
DepreciationRs m9071,2631,132-10.3%24.8%
InterestRs m930985937-4.8%0.8%
Profit before taxRs m1,5983,1803,57612.5%123.7%
TaxRs m5069771,0366.1%104.9%
Profit after taxRs m1,0932,2032,54015.3%132.5%
Gross profit margin%14.718.021.6
Effective tax rate%31.630.729.0
Net profit margin%4.77.810.6
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter grew 0.9% on a year-on-year (YoY) basis. The expenses were down by 5.8% YoY during the same period.
  • The company's operating profit increased by 48.0% YoY during the quarter. Consequently, operating profit margins witnessed a growth and stood at 21.6% in 1QFY21 as against 14.7% in 1QFY20.
  • Depreciation charges increased by 24.8% and finance costs increased by 0.8% YoY, respectively.
  • Other income increased by 3406.0% YoY during the quarter.
  • Net profit for the quarter increased by 132.5% YoY. Net profit margins during the quarter increased from 4.7% in 1QFY20 to 10.6% in 1QFY21.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter fell 15.3% on a quarter-on-quarter (QoQ) basis. The expenses were down by 18.9% QoQ during the same period.
  • The company's operating profit increased by 1.5% QoQ during the quarter. Consequently, operating profit margins witnessed a growth and stood at 21.6% in 1QFY21 as against 18.0% in 4QFY20.
  • Net profit for the quarter increased by 15.3% QoQ, while net profit margins increased from 7.8% in 4QFY20 to 10.6% in 1QFY21.

To see how GLENMARK PHARMA has performed over the last eight quarters,please visit here.

Today at 1pm: Watch special replay of Explosive Profits Summit

GLENMARK PHARMA Share Price Performance

Over the last one year,GLENMARK PHARMA share price has moved up from Rs 383.9 to Rs 476.7, registering a Gain of Rs 92.8 or around 24.2%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 18,438.7 (up 0.3%). Over the last one year it has moved up from 12,875.4 to 18,438.7, a gain of 5,563 points (up 43.2%).

Overall, the S&P BSE SENSEX is up 5.9% over the year.

Current Valuations

At the current price of Rs 476.7, the price to earnings (P/E) ratio of GLENMARK PHARMA stands at 14.6 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 2.4 times.

Equitymaster requests your view! Post a comment on "GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5%". Click here!

  

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

Not Infosys or Wipro. India's Next Wealth Creators Could Be Drone Stocks(Profit Hunter)

Nov 25, 2020

India's drones directorate signals the next big defence tech multibaggers.

It's Time to Book Profits(Fast Profits Daily)

Nov 27, 2020

In my first video on Equitymaster, I want to introduce you my proprietary greed and fear index. It's telling us to book some profits in the market.

How the New Margins Will Impact You(Fast Profits Daily)

Nov 25, 2020

The new rules on margins will come into effect from 1st December. Are you ready?

Is this Sector the Best Contrarian Bet Right Now?(Profit Hunter)

Nov 23, 2020

The risk reward ratio in this beaten down sector may have finally turned for the better.

The Price of Dying, the Cost of Living(The Honest Truth)

Nov 20, 2020

Ajit Dayal presents a cost benefit analysis of the various types of response to covid around the world.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Dec 1, 2020 10:32 AM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS